Neurocrine's total assets for Q1 2025 were $3.69B, a decrease of -0.83% from the previous quarter. DE:NB3 total liabilities were $1.15B for the fiscal quarter, a 2.04% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.